Private Capital Group’s Myriad Genetics MYGN Stock Holding History

Private Capital Group’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-13	Closed	–	–	2066
2020 Q2	$0	Hold	13	–	–	﹤0.01%	2093
2020 Q1	$0	Sell	13 -36	-73%	-$761	﹤0.01%	2075
2019 Q4	$1K	Sell	49 -14	-22%	-$385	﹤0.01%	1823
2019 Q3	$2K	Sell	63 -213	-77%	-$6.21K	﹤0.01%	1908
2019 Q2	$10K	Buy	276 +213	+338%	+$6.02K	﹤0.01%	1402
2019 Q1	$2K	Buy	63 +5	+9%	+$152	﹤0.01%	1911
2018 Q4	$2K	Sell	58 -226	-80%	-$8.13K	﹤0.01%	1892
2018 Q3	$13K	Buy	284 +8	+3%	+$356	﹤0.01%	1346
2018 Q2	$10K	Buy	+276	New	+$9.32K	﹤0.01%	1432

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Private Capital Group's MYGN Position: Q3 2020 in Review

Private Capital Group sold out of Myriad Genetics (MYGN) in Q3 2020, closing a stake of 13 shares.

Private Capital Group first reported a position in MYGN in Q2 2018 and held it in 9 quarters. The position peaked at $13K in Q3 2018. 192 funds tracked by Wall St. Rank hold MYGN as of Q3 2020.

Private Capital Group reported no remaining Myriad Genetics position as of Q3 2020 after selling out during the quarter.
Private Capital Group sold 13 Myriad Genetics shares in Q3 2020.
Private Capital Group first reported a position in Myriad Genetics in Q2 2018 and held it in 9 quarters.
Private Capital Group's Myriad Genetics position peaked at $13K in Q3 2018.
192 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2020.

Based on Private Capital Group's 13F filing for Q3 2020, filed 12 Nov 2020.